Tannate compositions and methods of treatment

  • US 6,509,492 B1
  • Filed: 09/14/2001
  • Issued: 01/21/2003
  • Est. Priority Date: 08/31/2001
  • Status: Expired due to Term
First Claim
Patent Images

1. A liquid suspension for treating upper respiratory indications comprising pseudoephedrine tannate, chlorpheniramine tannate and dextromethorphan tannate, wherein the concentration of pseudoephedrine tannate in the composition is 75-300 mg per 5 mL, the concentration of chlorpheniramine tannate in the composition is 4-6 mg per 5 mL, and the concentration of dextromethorphan tannate in the composition is 10-30 mg per 5 mL.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×